HVTN 702 is but one of many vaccine trials underway, researchers note.
Health care providers and educators need to acknowledge the impact of clinical bias and reframe sexual health education when it comes to tending to cisgender women's needs, Chase Alston writes.
This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.
What Needs to Happen Before California Pharmacies Can Sell PrEP and PEP Without an Initial Prescription
Pharmacists will increasingly play a role in pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) access in California.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
Providers, payers, and health systems need to catch up, said Melanie Thompson, M.D., at the ACTHIV conference.
A single drug dose, taken no more than once a month, to treat HIV: It's no longer the stuff of idle fantasy. But in a world stuffed with excellent once-a-day drugs, will long-acting meds have value?
The U.S. National Institutes of Health is seeking public comment on a proposal for "establishing a comprehensive, searchable resource of NIH-funded research results and providing free access for all" -- but with important limitations. The proposal, s...